Insider Buying: Altimmune, Inc. (ALT) Director Acquires 33,315 Shares of Stock

Altimmune, Inc. (NYSEARCA:ALT) Director Derace L. Schaffer purchased 33,315 shares of the business’s stock in a transaction on Thursday, November 30th. The shares were acquired at an average price of $1.91 per share, for a total transaction of $63,631.65. Following the completion of the acquisition, the director now directly owns 274,238 shares in the company, valued at approximately $523,794.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Altimmune, Inc. has a 12 month low of $49.37 and a 12 month high of $54.24.

Separately, Piper Jaffray Companies initiated coverage on Altimmune in a report on Monday, October 9th. They set an “overweight” rating and a $6.00 price target on the stock.

ILLEGAL ACTIVITY WARNING: “Insider Buying: Altimmune, Inc. (ALT) Director Acquires 33,315 Shares of Stock” was first published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/30/insider-buying-altimmune-inc-alt-director-acquires-33315-shares-of-stock.html.

About Altimmune

iShares Diversified Alternatives Trust (the Trust) is a commodity pool. The investment objective of the Trust is to maximize absolute returns from its investments in certain futures and/or forward contracts. The Trust holds long and/or short positions in foreign currency forward contracts and exchange-traded futures contracts involving assets, such as commodities, currencies, interest rates or certain eligible stock and/or bond indices.

Insider Buying and Selling by Quarter for Altimmune (NYSEARCA:ALT)

Receive News & Ratings for Altimmune Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply